Clik here to view.
Delcath touts 500th commercial Chemosat treatment in Europe
Delcath Systems (NSDQ:DCTH) said today that doctors in Europe performed the 500th percutaneous hepatic perfusion therapy treatment using Delcath’s Chemosat delivery system. The drug-device combo has...
View ArticleClik here to view.
Intarcia slashes headcount after FDA rejects diabetes drug-device combo
Four months after the FDA rejected its diabetes drug-eluting implant, privately-held Intarcia Therapeutics has cut 60 employees and received a clinical hold for two of its ongoing marketing studies,...
View ArticleClik here to view.
Cam Med partners with JDRF to develop flexible, bandage-like insulin patch pump
Medical device startup Cam Med has partnered with JDRF to develop an ultra-thin, flexible insulin patch pump to be used with next-generation artificial pancreas systems. The goal of the partnership is...
View ArticleClik here to view.
Novo Nordisk launches two new diabetes drugs in U.S.
Novo Nordisk (NYSE:NVO) today launched two new diabetes medications in pharmacies across the U.S. The Danish company’s Ozempic product is a once-weekly GLP-1 receptor agonist designed to boost glycemic...
View ArticleClik here to view.
Amiko wins CE Mark to integrate drug sensor tech into inhalers
Amiko Digital Health said today that it received CE Mark clearance to integrate its Respiro medication sensor tech with Teva Pharmaceuticals‘ (NYSE:TEVA) Spiromax inhaler, Chiesi‘s Nexthaler device and...
View ArticleClik here to view.
Portal Instruments uses speed to tackle needle-free drug delivery
Nobody likes to be on the receiving end of a shot. Studies have found that needle anxiety keeps people from getting important medications, like the flu vaccine, and can even stop people from taking...
View ArticleClik here to view.
BTG touts one-year follow-up data for Ekos pulmonary embolism therapy
BTG (LON:BTG) touted results today from a one-year follow-up of pulmonary embolism patients who received the company’s Ekos therapy in its Optalyse PE trial. Researchers studied the 12-month outcomes...
View ArticleClik here to view.
Study: Long-term use of inhaled corticosteroids may heighten risk of bone...
Researchers reported this month that in men and women with chronic obstructive pulmonary disease, long-term use of inhaled corticosteroids may be linked to an increased risk of bone fractures. Previous...
View ArticleClik here to view.
Teva inks deal to test drugs with ProBioGen’s artificial lymph node tech
Teva Pharmaceuticals (NYSE:TEVA) has inked a non-exclusive licensing deal to use ProBioGen‘s human artificial lymph node technology in the preclinical testing of the pharma company’s drug candidates....
View ArticleClik here to view.
Sales for Sanofi’s U.S. diabetes biz fall -30% in Q4
Shares in Sanofi (NYSE:SNY) fell today after the French pharmaceutical giant missed expectations on Wall Street with its 4th quarter and full-year financial results. The company faced particular...
View ArticleClik here to view.
Impel NeuroPharma touts proof-of-concept trial for intranasal migraine drug
Privately-held biotech Impel NeuroPharma touted positive results today from a Phase I trial of its acute migraine headache therapy. The Seattle-based company’s drug is delivered intranasally using its...
View ArticleClik here to view.
FDA rejects Novartis’ Advair generic, leaving GSK without rival
GlaxoSmithKline (NYSE:GSK) was granted a temporary win today after Novartis‘ (NYSE:NVS) Sandoz unit reported that the FDA rejected its application for a generic version of the company’s blockbuster...
View ArticleClik here to view.
Novocure lands $150m term loan
Novocure (NSDQ:NVCR) has inked a $150 million term loan agreement with Pharmakon Advisors’ investment fund, BioPharma Credit. The St. Helier, N.J.-based company plans to set aside some of the new funds...
View ArticleClik here to view.
Surmodics misses sales estimates in Q1
Shares in Surmodics (NSDQ:SRDX) fell slightly today after the medical device maker missed expectations on Wall Street with its first quarter results. The Eden Prairie, Minn.-based company swung to a...
View ArticleClik here to view.
pSivida touts 12-month data from Ph3 trial of Durasert ocular insert
pSivida (NSDQ:PSDV) touted results today from a second Phase III trial that the company conducted for its three-year posterior segment uveitis treatment. The 153-patient study found that there was a...
View ArticleClik here to view.
Teva shares tumble after “challenging” Q4, FY17
Shares in Teva Pharmaceuticals (NYSE:TEVA) fell today after the pharmaceutical company missed sales expectations on Wall Street with its fourth quarter results. The Israel-based company posted a net...
View ArticleClik here to view.
Rani Therapeutics nabs $53m for robotic pill injection tech
Rani Therapeutics has raised $53 million to support manufacturing as it gears up for clinical trials of its robotic pill technology. New investors like GeneScience Pharmaceuticals and Shire (NSDQ:SHPG)...
View ArticleClik here to view.
Novo Nordisk’s once-weekly Type II diabetes med approved in Europe
The European Commission has approved Novo Nordisk‘s (NYSE:NVO) once-weekly semaglutide drug, Ozempic, as a treatment for adults with Type II diabetes. The GLP-1 analogue’s label in Europe recommends...
View ArticleClik here to view.
Tandem Diabetes Care prices $60m offering
Tandem Diabetes Care (NSDQ:TNDM) has priced an underwritten public offering of 30 million shares of common stock at $2.00 apiece. The San Diego, Calif.-based company said it expects to reel in $60...
View ArticleClik here to view.
Innoviva posts Street-beating Q4, FY17 earnings
Shares in Innoviva (NSDQ:INVA) rose today after the company topped expectations on Wall Street with its fourth quarter and full-year financial results. The Brisbane, Calif.-based company posted profits...
View Article